Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Phase 2

Conditions: The Neoadjuvant Therapy

Interventions: Drug: Ribocyclib, fulvestrant, triptorelin
Drug: Doxorubicin, cyclophosphamide, paclitaxel

First Posted Date: 2021-02-15

Last Posted Date: 2021-02-15

Lead Sponsor: Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Target Recruit Count: 120

Registration Number: NCT04753177

Locations: 🇷🇺
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary, St-Peterburg, Russian Federation

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Phase 3

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: Triptorelin pamoate 15mg

First Posted Date: 2021-02-03

Last Posted Date: 2024-08-01

Lead Sponsor: Ipsen

Target Recruit Count: 32

Registration Number: NCT04736602

Locations: 🇨🇳
Tangshan Maternal & Child Health Hospital, Tangshan, China
🇨🇳
Chengdu Women's and Children's Central Hospital, Chengdu, China
🇨🇳
Jiangxi Provincial Children's Hospital, Nanchang, China

and more 4 locations

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Phase 4

Completed

Conditions: In Vitro Fertilization
Infertility
Intracytoplasmic Sperm Injection
Polycystic Ovary Syndrome

Interventions: Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)

First Posted Date: 2021-01-27

Last Posted Date: 2023-10-24

Lead Sponsor: Damascus University

Target Recruit Count: 50

Registration Number: NCT04727684

Locations: 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Phase 4

Completed

Conditions: In Vitro Fertilization
Infertility
Polycystic Ovary Syndrome
Intracytoplasmic Sperm Injection

Interventions: Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)

First Posted Date: 2021-01-27

Last Posted Date: 2023-10-24

Lead Sponsor: Damascus University

Target Recruit Count: 50

Registration Number: NCT04727671

Locations: 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

Phase 4

Completed

Conditions: In Vitro Fertilization
Infertility
Intracytoplasmic Sperm Injection

Interventions: Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)

First Posted Date: 2021-01-26

Last Posted Date: 2023-10-24

Lead Sponsor: Damascus University

Target Recruit Count: 50

Registration Number: NCT04724343

Locations: 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

Phase 4

Completed

Conditions: In Vitro Fertilization
Intracytoplasmic Sperm Injection
Infertility

Interventions: Drug: Triptorelin acetate
Drug: Cetrorelix
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Drug: Human Chorionic Gonadotropin (hCG)

First Posted Date: 2021-01-26

Last Posted Date: 2023-10-24

Lead Sponsor: Damascus University

Target Recruit Count: 50

Registration Number: NCT04724486

Locations: 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Triptorelin
Drug: Exemestane
Drug: Nivolumab

First Posted Date: 2020-12-09

Last Posted Date: 2020-12-09

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 43

Registration Number: NCT04659551

Locations: 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹
Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹
Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy

and more 2 locations

DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

Phase 1

Recruiting

Conditions: Breast Cancer Female

Interventions: Drug: Triptorelin 3.75 MG Injection
Procedure: Transvaginal oocyte retrieval
Drug: Triptorelin Injection

First Posted Date: 2020-11-05

Last Posted Date: 2023-05-18

Lead Sponsor: Universitair Ziekenhuis Brussel

Target Recruit Count: 30

Registration Number: NCT04616729

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Boortmeerbeek, Brussels, Belgium
🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Vlaams-Brabant, Belgium

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Phase 3

Completed

Conditions: Infertility, Female

Interventions: Drug: Duphaston
Drug: Cetrotide Injectable Product
Drug: Gonadotropin
Drug: Decapeptyl
Drug: Combined Oral Contraceptive
Drug: Chorionic Gonadotropin
Drug: Cyclo-Progynova
Drug: progesterone

First Posted Date: 2020-09-03

Last Posted Date: 2022-02-17

Lead Sponsor: El Shatby University Hospital for Obstetrics and Gynecology

Target Recruit Count: 90

Registration Number: NCT04537078

Locations: 🇪🇬
Elshatby University Maternity Hospital, Alexandria, Egypt

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3

Recruiting

Conditions: Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Drug: Bicalutamide
Drug: Apalutamide
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Buserelin
Procedure: Computed Tomography
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin
Drug: Histrelin
Drug: Leuprolide
Procedure: Magnetic Resonance Elastography
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Relugolix
Drug: Triptorelin

First Posted Date: 2020-08-14

Last Posted Date: 2025-05-07

Lead Sponsor: NRG Oncology

Target Recruit Count: 2753

Registration Number: NCT04513717

Locations: 🇺🇸
HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Sands Cancer Center, Canandaigua, New York, United States

and more 587 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy